John Haurum is to help Synklino develop a treatment against cytomegalovirus (CMV) infection in patients undergoing transplantation. The virus infection is quite common and often relatively harmless, but it can be more severe for transplantation patients receiving treatment with immunosuppressant drugs. “Synklino has developed a novel, potent anti-CMV therapy, which efficiently eliminates CMV-infected cells in preclinical models of disease. I am very excited to work with the Synklino founder team, as they develop the therapy towards clinical testing,” says Haurum.